Close this search box.

What’s behind CVS’s changing adalimumab strategy

ARTICLE | Market Access

Company opens the door to biosimilars on its major formularies while partnering with AbbVie on a co-branded Humira

By Richard Guy, Biopharma Analyst

May 22, 2024 10:37 PM UTC

The innovative biologics industry needs a vibrant biosimilars market to justify premium pricing of its new drugs, but the commercial fortunes of several biosimilars have been poor. Humira biosimilars, for example, failed to achieve substantial market share after launching last year, largely due to AbbVie’s rebate practices.

Now, the removal by CVS Health Corp. (NYSE:CVS) of Humira adalimumab from its major formularies and the company’s decision to market a version of the originator co-branded with AbbVie Inc. (NYSE:ABBV) promise to shake things up. …